Sara van den Berg

20 Chapter 1 43. Pera, A., et al., CMV induces expansion of highly polyfunctional CD4+ T-cell subset coexpressing CD57 and CD154. J Leukoc Biol, 2016. 44. van de Berg, P.J., et al., Cytomegalovirus infection reduces telomere length of the circulating T-cell pool. J Immunol, 2010. 184(7): p. 3417-23. 45. Khan, N., et al., Cytomegalovirus seropositivity drives the CD8 T-cell repertoire toward greater clonality in healthy elderly individuals. J Immunol, 2002. 169(4): p. 1984-92. 46. Goronzy, J.J., et al., Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol, 2001. 75(24): p. 12182-7. 47. McElhaney, J.E., et al., The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine, 2012. 30(12): p. 2060-7. 48. Trzonkowski, P., et al., Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination - An impact of immunosenescence. Vaccine, 2003. 21(25-26): p. 3826-3836. 49. Merani, S., et al., Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage. Exp Gerontol, 2018. 107: p. 116-125. 50. Derhovanessian, E., et al., Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core proteins in the elderly. J Immunol, 2014. 193(7): p. 3624-31. 51. Frasca, D., et al., Cytomegalovirus (CMV) seropositivity decreases B cell responses to the influenza vaccine. Vaccine, 2015. 33(12): p. 1433-9. 52. den Elzen, W.P., et al., Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. Vaccine, 2011. 29(29-30): p. 4869-74. 53. Furman, D., et al., Cytomegalovirus infection enhances the immune response to influenza. Science Translational Medicine, 2015. 7(281). 54. Strindhall, J., et al., Humoral response to influenza vaccination in relation to pre-vaccination antibody titres, vaccination history, cytomegalovirus serostatus and CD4/CD8 ratio. Infect Dis (Lond), 2016. 48(6): p. 436-42. 55. Strandberg, T.E., K.H. Pitkala, and R.S. Tilvis, Cytomegalovirus antibody level and mortality among community-dwelling older adults with stable cardiovascular disease. JAMA, 2009. 301(4): p. 380-2. 56. Thomasini, R.L., et al., Aged-associated cytomegalovirus and Epstein-Barr virus reactivation and cytomegalovirus relationship with the frailty syndrome in older women. PLoS One, 2017. 12(7): p. e0180841. 57. Feinstein, L., et al., Does cytomegalovirus infection contribute to socioeconomic disparities in all- cause mortality? Mech Ageing Dev, 2016. 158: p. 53-61. 58. Haeseker, M.B., et al., Association of cytomegalovirus and other pathogens with frailty and diabetes mellitus, but not with cardiovascular disease and mortality in psycho-geriatric patients; a prospective cohort study. Immun Ageing, 2013. 10(1): p. 30. 59. Savva, G.M., et al., Cytomegalovirus infection is associated with increased mortality in the older population. Aging Cell, 2013. 12(3): p. 381-7. 60. Collerton, J., et al., Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ Study. Mech Ageing Dev, 2012. 133(6): p. 456-66. 61. Franceschi, C., M. Bonafe, and S. Valensin, Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine, 2000. 18(16): p. 1717-20.